Company profile

Ticker
BIO
Exchange
Website
CEO
Norman D. Schwartz
Employees
Incorporated
Location
Fiscal year end
Former names
Bio Rad Laboratories Inc
SEC CIK
IRS number
941381833

BIO stock data

(
)

Calendar

31 Jul 20
3 Aug 20
31 Dec 20

News

Company financial data Financial data

Quarter (USD) Jun 20 Mar 20 Dec 19 Sep 19
Revenue 536.88M 571.64M 624.5M 560.6M
Net income 966.43M 685.91M 553.5M -258.8M
Diluted EPS 32.15 22.72 18.31 -8.68
Net profit margin 180% 120% 88.63% -46.16%
Operating income 51.74M 74.37M 59.21M 57.46M
Net change in cash 4.03M -57.12M 99.6M -19.61M
Cash on hand 607.58M 603.55M 660.67M 561.07M
Cost of revenue 243.89M 254.28M 293.99M 253.61M
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 2.31B 2.29B 2.16B 2.07B
Net income 1.76B 365.61M 122.25M 26M
Diluted EPS 58.27 12.1 4.07 0.88
Net profit margin 76.08% 15.97% 5.66% 1.26%
Operating income 229.66M -103.34M 119.25M 55.72M
Net change in cash 229.15M 47.7M -72.44M -1.29M
Cash on hand 660.67M 431.53M 383.82M 456.26M
Cost of revenue 1.05B 1.07B 972.45M 929.74M

Financial data from company earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
12 Jun 20 Schwartz Norman D Bio-Rad B Common Stock Payment of exercise Dispose F No 448.85 21,860 9.81M 295,122
12 Jun 20 Schwartz Norman D Bio-Rad B Common Stock Option exercise Aquire M No 84.57 37,000 3.13M 316,982
12 Jun 20 Schwartz Norman D NQSO Bio-Rad B Common Stock Option exercise Dispose M No 84.57 37,000 3.13M 0
1 Jun 20 Crowley Michael Bio-Rad A Common Stock Sell Dispose S No 485.4 1,500 728.1K 2,310
13 May 20 Hutton Ronald W Bio-Rad A Common Stock Sell Dispose S No 457.35 443 202.61K 4,140.339
29 Apr 20 Last Andrew J. Bio-Rad A Common Stock Payment of exercise Dispose F No 436.27 346 150.95K 679.977
29 Apr 20 Last Andrew J. Bio-Rad A Common Stock Option exercise Aquire M No 0 1,000 0 1,025.977
29 Apr 20 Last Andrew J. RSU Bio-Rad A Common Stock Option exercise Dispose M No 0 1,000 0 4,000
29 Apr 20 Ajit Ramalingam RSU Bio-Rad A Common Stock Grant Aquire A No 0 1,384 0 1,384
74.8% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 398 385 +3.4%
Opened positions 59 81 -27.2%
Closed positions 46 51 -9.8%
Increased positions 143 136 +5.1%
Reduced positions 137 111 +23.4%
13F shares
Current Prev Q Change
Total value 6.51B 6.98B -6.7%
Total shares 18.59M 18.96M -2.0%
Total puts 36.1K 23.8K +51.7%
Total calls 18.4K 70.8K -74.0%
Total put/call ratio 2.0 0.3 +483.6%
Largest owners
Shares Value Change
BLK BlackRock 2.24M $783.58M -3.6%
Vanguard 2.01M $705.78M +1.8%
FMR 731.23K $256.34M +13.5%
STT State Street 686.69K $240.73M +4.5%
American Century Companies 641.12K $224.75M -10.8%
WFC Wells Fargo & Company 508.37K $178.21M -2.2%
Atlanta Capital Management Co L L C 455.35K $159.63M -39.3%
Westfield Capital Management 389.9K $136.68M -15.4%
Aqr Capital Management 386.1K $134.63M +20.7%
Alliancebernstein 384.48K $134.78M +1.6%
Largest transactions
Shares Bought/sold Change
Atlanta Capital Management Co L L C 455.35K -294.48K -39.3%
Norges Bank 0 -211.27K EXIT
Pelham Capital 184.18K +184.18K NEW
AMP Ameriprise Financial 217.01K +151.36K +230.6%
Millennium Management 121.62K -147.36K -54.8%
Artemis Investment Management 258.64K +146.09K +129.8%
Brown Advisory 344.29K +115.77K +50.7%
Marshall Wace 112.25K +111.39K +12967.8%
Hound Partners 109.95K +109.95K NEW
tru Independence 0 -104.07K EXIT

Financial report summary

?
Risks
  • Our reported financial results may be materially affected by changes in the market value of our investment in Sartorius AG.
  • We may incur losses in future periods due to write-downs in the value of financial instruments.
Management Discussion
  • Percentage sales growth in currency neutral amounts are calculated by translating prior period sales in each local currency using the current period monthly average foreign exchange rates for that currency and comparing that to current period sales.
  • Net sales (sales) for the second quarter of 2020 were $536.9 million compared to $572.6 million in the second quarter of 2019, a decrease of 6.2%.  Excluding the impact of foreign currency, second quarter 2020 sales decreased by approximately 4.4% compared to the same period in 2019. Currency neutral sales decreased in the Americas and Europe, partially offset with an increase in Asia.
  • The Life Science segment sales for the second quarter of 2020 were $252.1 million, an increase of 18.7% compared to the same period last year.  On a currency neutral basis, sales increased 20.0% compared to the second quarter in 2019. The currency neutral sales increase was primarily driven by growth in our PCR, Droplet Digital PCR, and Process Media products. Currency neutral sales increases occurred in Asia and Europe. Sales for the second quarter of 2020 benefited from product lines used for COVID-19 testing and research, offsetting a global slowness due to temporary lab closures related to the COVID-19 pandemic. Sales in North America and sales in other product lines were negatively impacted due to customer lab closures resulting from the COVID-19 pandemic.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: bearing, duty, eligible, Media, newly, outflow, overhead, prepaid, remeasured, remeasurement, reserve, settled, setup, tangible, threshold
Removed: Codification, comparative, component, daily, Expression, Gene, heavily, historically, investigated, rare, reissuance, restate, tolerable, Typing, Unregistered, variance

Patents

GRANT
Utility
Methods for analyzing DNA
28 Jul 20
The invention generally relates to methods for increasing the amount of DNA available for analysis when using partitioned samples and parallel processing.
GRANT
Utility
Systems and methods for fluorescence detection with a movable detection module
28 Jul 20
A fluorescence detection apparatus for analyzing samples located in a plurality of wells in a thermal cycler and methods of use are provided.
GRANT
Utility
Small nucleic acid quantification using split cycle amplification
21 Jul 20
Methods of detecting or quantifying short RNA or DNA molecules using split cycle amplification are provided.
GRANT
Utility
System and method for capturing and analyzing cells
21 Jul 20
A system and method for capturing and analyzing a set of cells, comprising: an array including a set of parallel pores, each pore including a chamber including a chamber inlet and a chamber outlet, and configured to hold a single cell, and a pore channel fluidly connected to the chamber outlet; an inlet channel fluidly connected to each chamber inlet of the set of parallel pores; an outlet channel fluidly connected to each pore channel of the set of parallel pores; a set of electrophoresis channels fluidly coupled to the outlet channel, configured to receive a sieving matrix for electrophoretic separation; and a set of electrodes including a first electrode and a second electrode, wherein the set of electrodes is configured to provide an electric field that facilitates electrophoretic analysis of the set of cells.
APP
Utility
Heat Pump Device and Assembly
16 Jul 20
A heat pump that includes a thermoelectric device(s) and a heat sink having a raised portion with a top surface for thermally coupling with a planar face of the thermoelectric device(s).